
Reflecting on 2024: a category sweep of the Nobels, AI enabled clinical readouts, and the first trillion dollar pharma in sight. We stand on the shoulders of giants. Looking to 2025: This is just the beginning. Make no small plans.
✓Dimension is a multistage, research oriented, investment firm partnering with companies across the frontiers of science and compute

Reflecting on 2024: a category sweep of the Nobels, AI enabled clinical readouts, and the first trillion dollar pharma in sight. We stand on the shoulders of giants. Looking to 2025: This is just the beginning. Make no small plans.

The world is multi-modal. Your data warehouse should be too! I’ve been a happy user of @lancedb since 2024, it’s a magical experience. Turns out your favorite AI labs agree :) Honored to partner with @changhiskhan @eddyxu

Excited to announce @_DimensionCap’s partnership with @changhiskhan, @eddyxu and the team at @lancedb! Lance has built the leading database for large scale, multimodal data. This data workload is increasingly common in large scale AI training and some of the top research groups working on frontier models, world models, robotics, etc have switched over to LanceDB. Excited for the journey ahead, more soon!


Today we’re announcing a collaboration with @Roche, a leader in AI-driven drug discovery. Roche will apply @chaidiscovery's platform to help accelerate discovery programs across a number of targets in its therapeutic areas.

Deals from Chai, just this year: - lilly - pfizer - bms - argenx - gsk - novartis - roche breakthrough magical technology is breaking the laws of biopharma business physics

I think Bruce is right there's an incentive and financial element that explains some of this phenomenon, that AI-centric orgs aren't pursuing novel targets/epitopes. For example, you'll hear some investors try to avoid stacking risks by marrying an edgy discovery platform/modality/mechanism with a known target. But that's definitely not all of the story. Firstly, all public evidence of AI-driven molecular design is a lagging indicator. If you're reading about it openly, it's probably many months behind the frontier, if not longer, and that matters because the slope of progress is so steep right now. Second, there's an enormous capability gulf between modalities. Antibodies are vastly ahead of small molecules, for example, so I wouldn't expect novel scaffolds to necessarily be popping up left and right yet. Third, I think the iid argument that ML models can't design molecules outside their training corpus is wrong today and increasingly wrong tomorrow. There's a lot of variability here, but models are increasingly capable of transfer learning to ood problems. They are doing a better job internalizing enough biophysics to generalize. We as a field are getting much better at post-training w/ verifiable rewards (and lots of molecular design tasks are verifiable at scale), so RL loops even on non-frontier models can quickly hill-climb on specific targets/families etc. Altogether, it's very early still, but the slope is wild and I will probably have to edit this tweet in six months.

Missed the live session? Don't worry, there's a recording. youtube.com/watch?v=xZQ8Bn27…

in few years time, we’ll look back and laugh at how inefficiently we used to develop new medicines. special shoutout to dimension portfolio company divergence labs that we’ve had the privilege of watching up close these past few months

hey look there’s a fund built for this very moment (cough cough @chaidiscovery @CoefficientBio @newlimit @enveda @modal, Axiom Bio, Divergence Labs, @achira_ai @AnthropicAI @MonteRosaTx ..)

🦾 Is biotech soon going to be full of zero- and one-employee biotech startups? Join me, @AndrewE_Dunn + Dimension's @SimonDBarnett about what the weird future might look like. Today 10:30am ET on @endpts Post-Hoc Live! endpoints.news/post-hoc-live…

So pumped to share our third volume of the @_DimensionCap Research magazine! These articles were enjoyable to write alongside my research colleagues @SimonDBarnett and @bauer_lesavage In this volume, we dive deep into the foundations and applications of AI models, from pre-training, post-training, and agentic use to the emerging bio data market. This volume also features my first research article on applying autoresearch for training machine learning models to predict protein thermostability. I assessed how frontier models approach hyperparameter tuning and discussed how such an approach can be synergistic with traditional Bayesian optimization sweeping and expert-guided search. Since the article’s publication in April, we have seen a tremendous amount of progress in recursive self-improvement for closed-loop scientific discovery, and this is only the beginning! Our goal here is to present these broad topics in a rigorous yet accessible manner for everyone, no matter if you’re a frontier ML researcher or a weekend biotech warrior. We very much hope you enjoy!

Excited to share our third volume of the @_DimensionCap Research magazine! These articles were a blast to write with my research colleagues @SimonDBarnett and @ChemVagabond, and I feel so lucky to get to brainstorm, debate, learn, and write about these topics alongside them both on a daily basis. You’ll probably notice a theme to a lot of these articles that we have written throughout 2026: the chronicles of us diving head first into AI model training, the data needed to feed them, and emergent applications of training at the frontier. One of my favorite articles I wrote this year was centered around the bio data market and why biological training data has such unique considerations compared to text data. Since I published this one back in June, the demand for high-quality, therapeutic-relevant bio data has become even more obvious, and I don’t see this demand slowing down. The impact that AI is and is going to have in bio is becoming increasingly apparent every day, and we can’t get there without the right datasets. Our goal here is to make these topics accessible and interesting to all, no matter if you’re a frontier ML researcher doing this work daily or brand new to the space and just trying to get a sense of it all. We very much hope you enjoy!

That's a wrap! Today, we're (@_DimensionCap) releasing the third volume of our Research Magazine. Before anything else, I want to shout out my tremendous research colleagues Bauer (@bauer_lesavage) and Frank (@ChemVagabond), who were both core contributors to this volume. We're also releasing a digital version: dimensioncap.com/research-ma… ~~~ Compared to previous magazines, our third work is more heavily focused on machine learning. That's by design. Dimension invests in all companies, small and large, spanning the continuum from compute to the life sciences. At our core, we love technical teams working on the hardest, most important problems. That means data center infrastructure, new networking protocols, new silicon, inference optimization, physical AI, lean/tech-enabled biotechs, data generation, and more. As such, we challenged ourselves to go deeper into the compute stack than ever before, and how it connects to various branches of science. This magazine is a small sliver of the proverbial 'research exhaust' that our team generates over the course of a few quarters. ~~~ One piece I want to highlight is Without Form and Void, which was my attempt at unifying my background in fluid mechanics, my admiration of clever inductive biases in ML, and a major industry chokepoint seldom talked about in CS circles, which is bioprocess scaling. It's also the first piece I've tried writing with this much history (back to Galileo). ~~~ We hope you like Vol. 3 and we can't wait to show you all what's in store in Vol. 4!

Dimension portfolio company, Divergence Labs cc: @bjing2016

Today, in collaboration with Anthropic, we’re excited to share rapid initial progress towards an antibody treatment for food allergy, which affects over 200 million people worldwide, discovered with the help of Claude. At Divergence Labs, we believe that AI can unlock the next generation of antibody therapeutics with more effective mechanisms than before. Such mechanisms are urgently needed in food allergy, which involve overcoming one of the tightest affinity protein pairs in immunology, IgE and its receptor FcεRI, on mast cells. Treatment with Xolair—the only approved antibody for food allergy—sequesters circulating IgE, but mast cells remain sensitized for weeks to months due to the extraordinarily slow dissociation of IgE from FcεRI. We envision a treatment that actively pulls IgE off of FcεRI, without waiting for natural dissociation. Like picking a lock, this requires the right combination of geometry and force. Our research team, working with Claude, ideated on mechanisms to accomplish this disruption, and converged on an antibody format with two arms with different functions and epitopes. Within one month, we designed, synthesized, and experimentally confirmed the biophysical function of the two arms, which we are now assembling into full therapeutic formats.